TY - JOUR
T1 - Current pharmaceutical treatments and alternative therapies of parkinson’s disease
AU - Dong, Jie
AU - Cui, Yanhua
AU - Li, Song
AU - Le, Weidong
N1 - Funding Information:
This review was supported by grants from the National Natural Science Foundation of China (81370470 and 81430021), the Program for Liaoning Innovative Research Team in University (LT2015009).
Publisher Copyright:
© 2016 Bentham Science Publishers.
PY - 2016/5/1
Y1 - 2016/5/1
N2 - Over the decades, pharmaceutical treatments, particularly dopaminergic (DAergic) drugs have been considered as the main therapy against motor symptoms of Parkinson's disease (PD). It is proposed that DAergic drugs in combination with other medications, such as monoamine oxidase type B inhibitors, catechol-O-methyl transferase inhibitors, anticholinergics and other newly developed non-DAergic drugs can make a better control of motor symptoms or alleviate levodopa-induced motor complications. Moreover, non-motor symptoms of PD, such as cognitive, neuropsychiatric, sleep, autonomic and sensory disturbances caused by intrinsic PD pathology or drug-induced side effects, are gaining increasing attention and urgently need to be taken care of due to their impact on quality of life. Currently, neuroprotective therapies have been investigated extensively in pre-clinical studies, and some of them have been subjected to clinical trials. Furthermore, non-pharmaceutical treatments, including deep brain stimulation (DBS), gene therapy, cell replacement therapy and some complementary managements, such as Tai chi, Yoga, traditional herbs and molecular targeted therapies have also been considered as effective alternative therapies to classical pharmaceutics. This review will provide us updated information regarding the current drugs and non-drugs therapies for PD.
AB - Over the decades, pharmaceutical treatments, particularly dopaminergic (DAergic) drugs have been considered as the main therapy against motor symptoms of Parkinson's disease (PD). It is proposed that DAergic drugs in combination with other medications, such as monoamine oxidase type B inhibitors, catechol-O-methyl transferase inhibitors, anticholinergics and other newly developed non-DAergic drugs can make a better control of motor symptoms or alleviate levodopa-induced motor complications. Moreover, non-motor symptoms of PD, such as cognitive, neuropsychiatric, sleep, autonomic and sensory disturbances caused by intrinsic PD pathology or drug-induced side effects, are gaining increasing attention and urgently need to be taken care of due to their impact on quality of life. Currently, neuroprotective therapies have been investigated extensively in pre-clinical studies, and some of them have been subjected to clinical trials. Furthermore, non-pharmaceutical treatments, including deep brain stimulation (DBS), gene therapy, cell replacement therapy and some complementary managements, such as Tai chi, Yoga, traditional herbs and molecular targeted therapies have also been considered as effective alternative therapies to classical pharmaceutics. This review will provide us updated information regarding the current drugs and non-drugs therapies for PD.
KW - Cell transplantation
KW - Dopamine agonists
KW - Gene therapy
KW - Levodopa
KW - Motor symptoms
KW - Neuroprotection
KW - Non-motor symptoms
KW - Parkinson’s disease
UR - http://www.scopus.com/inward/record.url?scp=84964264743&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84964264743&partnerID=8YFLogxK
U2 - 10.2174/1570159X14666151120123025
DO - 10.2174/1570159X14666151120123025
M3 - Article
C2 - 26585523
AN - SCOPUS:84964264743
SN - 1570-159X
VL - 14
SP - 339
EP - 355
JO - Current Neuropharmacology
JF - Current Neuropharmacology
IS - 4
ER -